Whitepaper: Making MS-based glycan analysis easier
Posted: 4 March 2021 | Merck | No comments yet
Recent technological advances have made it easier to cope with the complexity of mass spectrometry (MS) based glycan analysis.
Glycosylation occurs in expression systems for producing biological drugs, creating a complex spectrum of N- and O-linked glycans that vary significantly with regards to in vivo stability, solubility, activity, safety, and efficacy. This makes glycoprotein analysis a challenging task that is performed at several levels: intact protein, subunit, peptide, and glycan. This white paper presents recent advances in MS-based methods to reduce the task’s complexity at all four levels.
Related content from this organisation
- Antibody-immunotherapy treatment shows benefit in serious endometrial cancer
- First-in-class biologic approved for rare lung disease
- Mycoplasma testing market expected to value nearly $2 million by 2031
- Pharmaceutical suspension market to witness accelerated growth
- Immunotherapy drug achieves trial-first in fifty years
Related topics
Analytical techniques, Biopharmaceuticals, Formulation, QA/QC, Regulation & Legislation, Research & Development (R&D)
